Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
November 10, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

NEW YORK and LONDON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
November 09, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Participate in the Jefferies London Healthcare Conference

NEW YORK and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
November 08, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer

Dr. Neylan has more than 20 years of experience in the development of biologic treatments from pre-clinical to post-marketing trials across a broad range of therapeutic areas, including specialty and...
October 31, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference

NEW YORK and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
October 28, 2022 16:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
September 27, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress

Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing supports Akari’s focused pipeline...
September 22, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
September 12, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces $12.75 Million Registered Direct Offering

NEW YORK and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
August 01, 2022 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Narrows Pipeline Focus

NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...